Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A new immunomodulating compound (AS-101) with potential therapeutic application.

B Sredni1, R R Caspi, A Klein

  • 1Department of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel.

Nature
|November 12, 1987
PubMed
Summary

A novel synthetic compound, AS-101, demonstrates immunomodulating properties with minimal toxicity. This compound stimulates lymphocyte activity and shows potential in treating immunosuppressive conditions and cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical profiles of four patients with Rett syndrome carrying a novel exon 1 mutation or genomic rearrangement in the MECP2 gene.

Clinical genetics·2006
Same author

Eta' photoproduction on the proton for photon energies from 1.527 to 2.227 GeV.

Physical review letters·2006
Same author

Measurement of two- and three-nucleon short-range correlation probabilities in nuclei.

Physical review letters·2006
Same author

[Ulcerative gingivostomatitis and peridontitis].

HNO·2006
Same author

Search for Theta+ (1540) Pentaquark in High-Statistics Measurement of gammap-->K0K+n at CLAS.

Physical review letters·2006
Same author

[Hematopoietic stem cell transplantation for severe sickle cell disease].

Revue medicale de Bruxelles·2006

Area of Science:

  • Immunology
  • Synthetic Chemistry
  • Pharmacology

Background:

  • Interleukin 2 (IL-2) and lymphokine-activated killer cells are used in cancer treatment but have toxic side effects.
  • Synthetic compounds that mimic cytokine action are of interest for modulating immune responses.
  • High doses of IL-2 required for therapy lead to significant toxicity.

Purpose of the Study:

  • To assess the immunomodulating properties and effects of the synthetic compound AS-101 on immunocompetent cells.
  • To evaluate the potential of AS-101 as a therapeutic agent with minimal toxicity.
  • To investigate AS-101's efficacy in conditions involving immunosuppression and cancer.

Main Methods:

  • In vitro assessment of AS-101's effects on human lymphocyte proliferation and IL-2 production.

Related Experiment Videos

  • In vitro and in vivo studies on mouse spleen cells to evaluate IL-2 and colony-stimulating factor (CSF) production.
  • Analysis of IL-2 receptor expression and intracellular calcium levels in lymphocytes exposed to AS-101.
  • Evaluation of AS-101's antitumour effects in mice and its impact on T-cell ratios in AIDS patient cells.

    • Main Results:

    • AS-101 induced proliferation and IL-2 production in human lymphocytes in vitro.
    • AS-101 enhanced IL-2 and CSF production in mouse spleen cells, both in vitro and in vivo.
    • AS-101 increased IL-2 receptor expression on lymphocytes and elevated intracellular calcium levels.
    • Systemic AS-101 administration showed antitumour effects in mice and improved OKT4/OKT8 ratios in AIDS patient cells.

    Conclusions:

    • AS-101 possesses significant immunomodulating properties with minimal toxicity.
    • The compound stimulates lymphocyte activation and function, potentially via increased intracellular calcium.
    • AS-101 demonstrates therapeutic potential for cancer and immunosuppressive conditions like AIDS.
    • Further research into AS-101 is warranted for clinical applications in immune-related disorders.